S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

AUPH Aurinia Pharmaceuticals Inc

5.42

0.04 (0.74%)

01 Jun 2024 - Closed

Delayed by 15 minutes

Aurinia Pharmaceuticals drops 12% after filing mixed shelf offering

To read the full story on Seeking Alpha, click here.

Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From May 2024 to Jun 2024

Click Here for more Aurinia Pharmaceuticals Charts.

Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Jun 2023 to Jun 2024

Click Here for more Aurinia Pharmaceuticals Charts.

Aurinia Pharmaceuticals Inc News

Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
Thursday 30 May 2024 (2 days ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 23 May 2024 (1 week ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 23 May 2024 (1 week ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 23 May 2024 (1 week ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 23 May 2024 (1 week ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 23 May 2024 (1 week ago) • Edgar (US Regulatory)

Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
Tuesday 14 May 2024 (3 weeks ago) • Business Wire

Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
Thursday 9 May 2024 (3 weeks ago) • Business Wire

Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
Tuesday 7 May 2024 (4 weeks ago) • Business Wire

Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
Thursday 2 May 2024 (1 month ago) • Business Wire

Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
Wednesday 1 May 2024 (1 month ago) • Business Wire

The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
Tuesday 30 April 2024 (1 month ago) • Business Wire

More Aurinia Pharmaceuticals Inc News Articles

Raymond James Financial, Inc.

Hightekers Token

FundX Investment

Aeries Technology

Franchise Bancorp Inc.

Hsbc Icav Gl Su

Equity Allocation Etf Mo...

Dorsey Wright Relative S...

PagSeguro Digital

FER HERINGER ON

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions